Acerta Pharma BV

🇳🇱Netherlands

Country: 🇳🇱Netherlands

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.acerta-pharma.com

Clinical Trials

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Phase 1

Completed

Conditions: Healthy Subjects
Hepatic Impairment
Hepatic Insufficiency

Interventions: Drug: acalabrutinib

First Posted Date: 2019-05-30

Last Posted Date: 2021-09-10

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 16

Registration Number: NCT03968848

Locations: 🇺🇸
Research Site, Knoxville, Tennessee, United States

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Chemoimmunotherapy
Drug: Acalabrutinib
Drug: Venetoclax
Drug: Obinutuzumab

First Posted Date: 2019-02-11

Last Posted Date: 2024-12-27

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 984

Registration Number: NCT03836261

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

Phase 1

Completed

Conditions: Non-hodgkin's Lymphoma
Diffuse Large B Cell Lymphoma
NHL
DLBCL

Interventions: Drug: AZD9150
Drug: Acalabrutinib
Drug: AZD5153
Drug: AZD6738
Drug: Hu5F9-G4
Drug: Rituximab

First Posted Date: 2018-05-17

Last Posted Date: 2022-08-15

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 30

Registration Number: NCT03527147

Locations: 🇬🇧
Research Site, Oxford, United Kingdom

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Ceralasertib
Drug: Acalabrutinib

First Posted Date: 2017-11-01

Last Posted Date: 2024-11-19

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 11

Registration Number: NCT03328273

Locations: 🇬🇧
Research Site, Southampton, United Kingdom

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Phase 1

Terminated

Conditions: DLBCL
Richter Syndrome

Interventions: Drug: acalabrutinib
Drug: vistusertib

First Posted Date: 2017-07-02

Last Posted Date: 2021-01-06

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 25

Registration Number: NCT03205046

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Phase 3

Active, not recruiting

Conditions: Lymphoma, Mantle Cell

Interventions: Drug: Acalabrutinib
Drug: Bendamustine
Drug: Rituximab
Drug: Placebo

First Posted Date: 2016-11-25

Last Posted Date: 2024-11-29

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 635

Registration Number: NCT02972840

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Acalabrutinib (ACP-196)
Drug: Rituximab
Drug: Idelalisib
Drug: Bendamustine

First Posted Date: 2016-11-22

Last Posted Date: 2024-11-27

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 310

Registration Number: NCT02970318

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Phase 3

Withdrawn

Conditions: Mantle Cell Lymphoma

Interventions: Drug: ibrutinib
Drug: acalabrutinib
Drug: rituximab

First Posted Date: 2016-04-13

Last Posted Date: 2016-05-13

Lead Sponsor: Acerta Pharma BV

Registration Number: NCT02735876

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Phase 1

Active, not recruiting

Conditions: Mantle Cell Lymphoma (MCL)

Interventions: Drug: Acalabrutinib in combination with BR
Drug: Acalabrutinib in combination with VR

First Posted Date: 2016-03-24

Last Posted Date: 2024-11-22

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 72

Registration Number: NCT02717624

Locations: 🇵🇱
Research Site, Warszawa, Poland

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Phase 2

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: ACP-196 (acalabrutinib)

First Posted Date: 2016-03-24

Last Posted Date: 2024-11-20

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 60

Registration Number: NCT02717611

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

Home Terms & Conditions Privacy Policy